1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Wounds - Pipeline Review, H1 2020, provides an overview of the Wounds (Dermatology) pipeline landscape.
Wound is a breakdown in the protective function of the skin (the loss of continuity of epithelium) with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/ organs caused by surgery, a blow, a cut, chemicals, heat/ cold, friction/ shear force, pressure or as a result of disease, such as leg ulcers or carcinomas. Signs and symptoms include redness or red streaks on the skin surrounding the wound, increased swelling to tenderness at the wound site, pus-like drainage or a foul smell from the wound and body chills or fever.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Wounds - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Wounds (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Wounds (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Wounds and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 10, 8, 56, 10 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 4 molecules, respectively.
Wounds (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Wounds (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Wounds (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Wounds (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Wounds (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Wounds (Dermatology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Wounds (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Wounds (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Wounds - Overview
- Wounds - Therapeutics Development
- Wounds - Therapeutics Assessment
- Wounds - Companies Involved in Therapeutics Development
- Wounds - Drug Profiles
- Wounds - Dormant Projects
- Wounds - Discontinued Products
- Wounds - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Wounds, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Wounds - Pipeline by AdiSave Inc, H1 2020
- Wounds - Pipeline by Agile Sciences Inc, H1 2020
- Wounds - Pipeline by Aiviva BioPharma Inc, H1 2020
- Wounds - Pipeline by AlgiPharma AS, H1 2020
- Wounds - Pipeline by Allander Biotechnologies LLC, H1 2020
- Wounds - Pipeline by Alliance Pharma Plc, H1 2020
- Wounds - Pipeline by AMNICELL Corp Ltd, H1 2020
- Wounds - Pipeline by Ankasa Regenerative Therapeutics Inc, H1 2020
- Wounds - Pipeline by Apidel SA, H1 2020
- Wounds - Pipeline by Aposcience AG, H1 2020
- Wounds - Pipeline by Araim Pharmaceuticals Inc, H1 2020
- Wounds - Pipeline by Arava Bio-Tech Ltd, H1 2020
- Wounds - Pipeline by Armata Pharmaceuticals Inc, H1 2020
- Wounds - Pipeline by Arrevus Inc, H1 2020
- Wounds - Pipeline by Auxagen Inc, H1 2020
- Wounds - Pipeline by Avalon GloboCare Corp, H1 2020
- Wounds - Pipeline by Axolo Pharma Inc, H1 2020
- Wounds - Pipeline by ZZ Biotech LLC, H1 2020
- Wounds - Dormant Projects, H1 2020
- Wounds - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Wounds, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AdiSave Inc
- Agile Sciences Inc
- Aiviva BioPharma Inc
- AlgiPharma AS
- Allander Biotechnologies LLC
- Alliance Pharma Plc
- AMNICELL Corp Ltd
- Ankasa Regenerative Therapeutics Inc
- Apidel SA
- Aposcience AG
- Araim Pharmaceuticals Inc
- Arava Bio-Tech Ltd
- Armata Pharmaceuticals Inc
- Arrevus Inc
- Auxagen Inc
- Avalon GloboCare Corp
- Axolo Pharma Inc
- Biomendics LLC
- Biotec Pharmacon ASA
- Canton Biotechnologies Inc
- CarthroniX Inc
- Cellphire Inc
- Clene Nanomedicine Inc
- Crioestaminal Saude e Tecnologia SA
- Daewoong Pharmaceutical Co Ltd
- Destiny Pharma Plc
- Exicure Inc
- Exopharm Ltd
- EyeGene Inc
- Factor Therapeutics Ltd
- FortuneRock (China) Ltd
- Gene Signal International SA
- Helixmith Co Ltd
- Histogen Inc
- Huons Global Co Ltd
- Ilya Pharma AB
- Krystal Biotech Inc
- LayerBio Inc
- Lipid Biologics LLC
- Living Cell Technologies Ltd
- Madam Therapeutics BV
- MangoGen Pharma Inc
- Marizyme Inc
- MediaPharma SRL
- MediWound Ltd
- MicroCures Inc
- Miragen Therapeutics Inc
- NellOne Therapeutics Inc
- Novion Technologies Inc
- Novopyxis Inc
- Omeros Corp
- Opal Biosciences Ltd
- Pacific Northwest Biotechnology LLC
- PhagoMed Biopharma GmbH
- Phoenicia Biosciences Inc
- QBiotics Ltd
- Regeneus Ltd
- Remedor Biomed Ltd
- Reponex Pharmaceuticals Aps
- Resolys Bio Inc
- Reven Pharmaceuticals Inc
- Revive Therapeutics Ltd
- Riptide Bioscience Inc
- Scarless Laboratories Inc
- SomaGenics Inc
- Synedgen Inc
- TGV-Inhalonix Inc
- Thesan Pharmaceuticals Inc
- Topadur Pharma AG
- Transwell Biotech Co Ltd
- Traverse Biosciences Inc
- Tumorend LLC
- Valitor Inc
- Vascular BioSciences
- Vasomune Inc
- viDA Therapeutics Inc
- Yabao Pharmaceutical Group Co Ltd
- Zih Yuan Tang Biotechnology Co Ltd
- ZZ Biotech LLC
